FDA Approves New Higher Dose of Semaglutide, Wegovy HD, for Weight Loss

The FDA approved semaglutide 7.2 mg (Wegovy HD), the highest dose for semaglutide to date, for long-term weight reduction. This new once-weekly injectable demonstrated a mean weight loss of 20.7% in the STEP UP (NCT05646706) phase 3 clinical trial, with approximately 1 in 3 participants achieving a weight loss of 25% or greater. This approval provides a potent new therapeutic option for adults with obesity or those who are overweight with at least 1 weight-related condition.¹

“Since its launch in 2021, Wegovy has transformed the lives of many people living with obesity and helped them achieve meaningful weight loss and important cardiometabolic benefits, including an unprecedented reduction in cardiovascular risk,” Mike Doustdar, president and CEO of Novo Nordisk, said in a news release. “Earlier this year, we launched the Wegovy pill, and with the accelerated approval of Wegovy HD, we are introducing a new offering for our injectable semaglutide that provides even greater weight loss of approximately 21%.”

The efficacy of the 7.2 mg dose remains substantial even among more complex patient populations. In the STEP UP T2D (NCT05649137) trial, which focused on adults with both obesity and type 2 diabetes, participants achieved a mean weight loss of 14.1%. Although this higher dosage offers the potential for greater weight reduction than the previously approved 2.4 mg dose, the FDA noted that it provided similar blood sugar-lowering effects compared with the lower dosage.^1,2

The regulatory path for Wegovy HD was exceptionally rapid, with the decision granted just 54 days after filing, according to the FDA. This marks the fourth approval under the Commissioner's National Priority Voucher (CNPV) pilot program, a trial initiative intended to move with unprecedented efficiency on products that address critical national health priorities and unmet medical needs.²

“The new FDA is moving with unprecedented efficiency on products that advance national priorities,” FDA Commissioner Martin Makary, MD, MPH, said in a news release. “Today’s approval is another demonstration of what the FDA can accomplish when we try bold new things.”

For pharmacists counseling patients, understanding the safety profile of this higher dose is essential. Although the overall safety and tolerability remain consistent with previous semaglutide trials, the higher dose was associated with more frequent reports of altered skin sensation, including sensitivity, pain, or burning. These sensations generally resolve on their own or with a dose reduction, but the FDA is conducting further investigations into this specific reaction.

The most common adverse effects remain gastrointestinal in nature, such as nausea, vomiting, and diarrhea. Additionally, Wegovy HD carries a boxed warning regarding the potential risk of thyroid C-cell tumors and is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

This approval arrives amidst a broader regulatory crackdown on the glucagon-like peptide-1 (GLP-1) market that directly impacts pharmacy practice. Earlier in March 2026, the FDA issued warning letters to 30 telehealth companies for the illegal marketing of compounded GLP-1 medications, citing misleading claims that suggested these products were identical to FDA-approved versions. Novo Nordisk has also initiated litigation against certain firms, alleging that independent testing of some compounded semaglutide products revealed impurities as high as 86%, posing risks of immunogenicity or anaphylaxis.³

Professional organizations such as the American Diabetes Association have cautioned against compounded GLP-1s due to quality and effectiveness uncertainties. Pharmacists are now positioned on the front lines, tasked with educating patients about the risks of knock-off products and guiding them toward FDA-approved therapies that have undergone rigorous premarket safety and efficacy reviews.³

Novo Nordisk expects to launch Wegovy HD in a single-dose pen in the US in April 2026.¹

READ MORE: Obesity Management Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Novo Nordisk A/S: Wegovy HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss. News release. Novo Nordisk. March 19, 2026. Accessed March 20, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916516

2. FDA approves fourth product under national priority voucher program, higher dose semaglutide. News release. FDA. March 19, 2026. March 20, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide

3. Gallagher A. FDA issues warnings to 30 telehealth companies against illegal marketing of compounded GLP-1 medications. Drug Topics. March 4, 2026. Accessed March 20, 2026. https://www.drugtopics.com/view/fda-issues-warnings-to-30-telehealth-companies-against-illegal-marketing-of-compounded-glp-1-medications